Calcimimetic agents and secondary hyperparathyroidism: Treatment and prevention

Nephrology Dialysis Transplantation

Volumn 17, Issue 2, 2002, Pages 204-207

  Goodman, William G ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM; CALCIUM CHANNEL STIMULATING AGENT; CINACALCET; PARATHYROID HORMONE; PLACEBO; R 568; STEROL; UNCLASSIFIED DRUG; VITAMIN D;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MASS; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; HORMONE RELEASE; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; MOUSE; NONHUMAN; PARATHYROID GLAND; PARATHYROID HYPERPLASIA; PRIORITY JOURNAL; RAT; SECONDARY HYPERPARATHYROIDISM;

EID: 0036181957     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.2.204     Document Type: Article

References (23)

1. Calcium receptors as novel drug targets
2. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism
3. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication
4. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism
5. NPS R-568: A type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium
6. Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue
7. Parathyroid gland function and the set point for PTH release: Understanding the available data
8. Recent developments in the management of secondary hyperparathyroidism
9. 2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568
10. 2+-sensing receptor in primary and uremic secondary hyperparathyroidism
11. Altered instantaneous and calcium-modulated oscillatory PTH secretion patterns in patients with secondary hyperparathyroidism
12. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial
13. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats
14. Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia
15. Calcimimetic agents for the treatment of hyperparathyroidism
16. The calcimimetic AMG-073 reduces parathyroid hormone (PTH), phosphorus (P), and calcium x phosphorus product (Ca x P) in patients with ESRD and secondary hyperparathyroidism
17. Multiple doses of the calcimimetic, AMG-073, reduce parathyroid hormone levels in a dose dependent manner in hemodialysis patients with secondary hyperparathyroidism
18. Association of serum phosphorus and calcium x phosphorus product with mortality risk in chronic hemodialysis patients: A national study
19. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis
20. Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease
21. Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism
22. Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats
23. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets and osteomalacia, but not alopecia in vitamin D receptor-ablated mice